What it’s for
- Diabetes, heart failure and kidney disease in eligible patients
A class of prescription medicines that increase glucose excretion through the kidneys.
Purpose, evidence and practical considerations.
Large trials support benefits for particular drugs and patient groups. Those results do not establish a general anti-ageing treatment for people without the studied conditions.
Confidence: strong
Risks include genital fungal infection, volume depletion, hypotension and rare but serious ketoacidosis that can occur with near-normal glucose. Surgery, fasting, acute illness and very-low-carbohydrate diets increase concern. Kidney function, diabetes type, infection risk and concurrent diuretics require clinician management; these are prescription drugs, not casual longevity supplements.
SGLT2 inhibitors reduce renal glucose and sodium reabsorption, producing glucosuria and natriuresis. Their heart-failure and kidney benefits appear partly independent of glucose lowering, but mechanisms remain incompletely resolved and benefits are drug- and indication-specific.
Regulatory status: prescription-only in the United States, the European Union, UK, and Canada. Not OTC. Not a supplement. Not approved anywhere as a treatment for aging, healthspan, or “longevity.”
How people use it, with their schedules, context and original sources.
10 mg · Daily
longevity intervention and calorie-restriction mimetic in animal experiments
Dose and schedule patterns reported in public protocols; these are observations, not prescribing advice. Private and hidden usage is excluded.
daily
Brand variants reported in public protocols. Private entries are excluded, and inclusion is not an endorsement.
These share a protocol with this intervention. This does not establish that they work together or are suitable alternatives.